ALKEM LABORATORIES LTD. (539523) — Latest Corporate Announcements
₹5,222
+₹17.00 (+0.33%)
Market Cap
₹62,436.84 Cr
P/E Ratio
28.94
52W Range
₹5051 – ₹5933.5
Corporate Actions & Regulatory Filings
Alkem Laboratories Limited has informed the Exchange regarding Appointment of Mr Laxmikant Tiwari as Senior Management Personnel of the company w.e.f. October 12, 2026.
Alkem Laboratories Limited has informed the Exchange regarding Appointment of Mr Nilesh Vartak as Senior Management Personnel of the company w.e.f. October 12, 2026.
Announcement under Regulation 30 (LODR)-Change in Management
Announcement under Regulation 30 (LODR)-Cessation
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Closure of Trading Window
Disclosure Under Regulation 30 Of SEBI (LODR) Regulations
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Announcement under Regulation 30 (LODR)-Change in Management
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Shareholder Meeting / Postal Ballot-Outcome of AGM
Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Shareholder Meeting / Postal Ballot-Outcome of Court Convened Meeting
Announcement under Regulation 30 (LODR)-Newspaper Publication
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Closure of Trading Window
Announcement under Regulation 30 (LODR)-Investor Presentation
Financial Results (Quarterly & Annual)
| Quarter / Period | Meeting / Outcome Date | Status | Filing Details |
|---|---|---|---|
| Quarter Ended 30-Jun-2026 (Q1 FY27) | 14 Aug 2026 | Declared |
Results- Unaudited Financial Results For Quarter Ended June 30, 2026
📄 View Quarter Ended 30-Jun-2026 (Q1 FY27) Results PDF ↗ |
| Year Ended 31-Mar-2026 (Q4 FY26) (STD & CONSOL) | 28-May-2026 | Declared | Meeting of the Board of Directors of the Company is scheduled to be held on Thursday, 28th May, 2026, inter alia:(i) To consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the quarter and financial year ended 31st March, 2026; and (ii) To consider and recommend Final Dividend, if any, for financial year ended 31st March, 2026. |
| Quarter Ended 31-Dec-2025 (Q3 FY26) | 13-Feb-2026 | Declared | Notice of meeting of the Board of Directors of Alkem Laboratories Limited ( the Company ) |
| Quarter Ended 30-Sep-2025 (Q2 FY26) (STD & CONSOL) | 13-Nov-2025 | Declared | Notice of meeting of the Board of Directors of the Company scheduled to be held on Thursday, 13th November, 2025, inter alia, to consider and approve the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and half year ended 30th September, 2025. |
| Quarter Ended 30-Jun-2025 (Q1 FY26) | 12-Aug-2025 | Declared | To consider and approve the financial results for the period ended Jun 30, 2025 |
| Year Ended 31-Mar-2025 (Q4 FY25) | 29-May-2025 | Declared | To consider and approve the financial results for the period ended March 31, 2025 and final dividend, if any |
| Quarter Ended 31-Dec-2024 (Q3 FY25) | 07-Feb-2025 | Declared | To consider and approve the financial results for the period ended December 31, 2024 and dividend |
| Quarter Ended 30-Sep-2024 (Q2 FY25) | 13-Nov-2024 | Declared | To consider and approve the financial results for the period ended September 30, 2024 |
| Quarter Ended 30-Jun-2024 (Q1 FY25) | 09-Aug-2024 | Declared | To consider and approve the financial results for the period ended Jun 30, 2024 |
| Year Ended 31-Mar-2024 (Q4 FY24) | 29-May-2024 | Declared | To consider and approve the financial results for the period ended March 31, 2024 and final dividend |
| Quarter Ended 31-Dec-2023 (Q3 FY24) | 09-Feb-2024 | Declared | To consider and approve the financial results for the period ended December 31, 2023 and dividend |
| Quarter Ended 30-Sep-2023 (Q2 FY24) | 07-Nov-2023 | Declared | To consider and approve the financial results for the period ended September 30, 2023 |
Track Related Peer Equities
Related Research Guides & Regulatory Playbooks
Frequently Asked Questions about ALKEM LABORATORIES LTD. BSE Disclosures
What is the latest BSE announcement by ALKEM LABORATORIES LTD.?
The latest BSE disclosure by ALKEM LABORATORIES LTD. (ALKEM), filed on 12-Oct-2026 16:09:41, is: "Alkem Laboratories Limited has informed the Exchange regarding Appointment of Mr Laxmikant Tiwari as Senior Management Personnel of the company w.e.f. October 12, 2026.". Bsenexus tracks every official filing for ALKEM LABORATORIES LTD. with AI-powered summaries on its announcements feed.
When is ALKEM LABORATORIES LTD.'s next board meeting?
No upcoming board meeting is currently tracked for ALKEM LABORATORIES LTD.. Companies disclose meeting intimations under SEBI LODR, and scheduled dates appear on the Bsenexus Results Calendar.
When does ALKEM LABORATORIES LTD. declare quarterly results?
Under SEBI (LODR) Regulation 33, listed companies submit quarterly unaudited results within 45 days of the quarter ending, and annual audited figures within 60 days. ALKEM LABORATORIES LTD.'s recent results history is tabulated above. Track scheduled board meetings on the Bsenexus Results Calendar.